Clinical trial NCT05034874: Multiple-Dose Study to Evaluate the Safety and Efficacy of IXT-m200
Official title: A Phase 2, Double-Blind, Randomized, Placebo-Controlled, Multiple-Dose Study to Evaluate the Safety and Efficacy of IXT-m200 in Treatment-Seeking Individuals With Methamphetamine Use Disorder
Study type: INTERVENTIONAL
Overall status: TERMINATED
Phase: PHASE2
Conditions: Methamphetamine-dependence
Methamphetamine Abuse
Lead sponsor: InterveXion Therapeutics, LLC
Sponsor class: INDUSTRY
Collaborators: name: National Institute on Drug Abuse (NIDA)
First posted: 2021-09-05
Enrollment: 61
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: This Phase 2 study will evaluate the safety and efficacy of monthly intravenous doses of IXT-m200 in treatment-seeking individuals with methamphetamine (METH) use disorder. The hypothesis are that following an initial relapse, IXT-m200 will reduce the occurrence of stimulant-positive saliva samples compared to placebo and improve the signs and symptoms of METH Use Disorder (MUD).


Eligibility criteria: Eligible participants will:

1. Be at least 18 years of age at the time of study consent;
2. Meet Diagnostic and Statistical Manual of Mental Disorders (DSM)-5 criteria for Substance Use Disorder associated with methamphetamine;
3. Be treatment-seeking methamphetamine users with at least 1 methamphetamine or amphetamine positive specimen during the screening period;
4. Be able and willing to read, comprehend, and give Authorization for Use/Disclosure of Health Information (HIPAA) and informed consent;
5. Be willing to comply with study instructions and dosing, agree to make all appointments, and complete the entire course of the study;
6. Agree to use protocol-specified method(s) of birth control throughout study participation;
7. Agree to adhere to Lifestyle Considerations throughout study duration;
8. Have access to a smartphone or other device capable of supporting the study app;
9. Successfully complete app-based training program as evidenced by completion of at least 75% of daily drug use surveys and assigned saliva drug screens (two of which must be valid) in ≤30 days from the screening visit during the screening period.

Eligible participants will NOT:

1. Have current dependence, defined by DSM-5 criteria, on any psychoactive substance (i.e., opioids or benzodiazepines), other than methamphetamine or nicotine (any severity). Mild severity dependence on alcohol or marijuana is allowed;
2. Be currently taking certain other drugs and medications, including: "designer drugs" (e.g., 3,4-methylenedioxyMETH (MDMA, Ecstasy, Adam, XTC) and its N-dimethyl metabolite methylenedioxyamphetamine (MDA), anti-orexigenic drugs (including over-the-counter medications for weight loss), or be chronic users of phenethylamine compounds (e.g., phenylpropanolamine, ephedrine, pseudoephedrine, amphetamine, phentermine, phenmetrazine, methylphenidate, diethylpropion, and propylhexedrine);
3. Have a known contraindication or sensitivity to IXT-m200 based on known allergies to other monoclonal antibodies, any inactive ingredient of IXT-m200, or any other products required for the study procedures;
4. Have a history of severe allergy (rash, hives, breathing difficulty, etc) to any medications;
5. Have a history of allergic or environmental bronchial asthma within the past 3 years;
6. Have a current diagnosis of anorexia nervosa or bulimia disorder;
7. Have a history of unstable cardiovascular disease that is not adequately controlled at the time of eligibility determination;
8. Be mandated by the court to obtain treatment for methamphetamine-dependence where such mandate required the results of methamphetamine testing to be reported to the court;
9. Have positive saliva drug screens for psychoactive substances other than amphetamines at the screening visit;
10. Be expected to fail to complete the study protocol due to probable incarceration or relocation from the clinic area, or any clinically significant mental or physical illness within a 1-year prior, that would impact compliance with trial requirements;
11. Have clinically significant laboratory values (outside of normal limits). The following specified ranges are allowable:

    1. Liver function tests (total, direct, and indirect bilirubin, aspartate transaminase, alanine aminotransferase, gamma-glutamyl transferase, lactate dehydrogenase, and alkaline phosphatase) \<3 times the upper limit of normal, and
    2. Kidney function tests (creatinine and BUN) \<2 times the upper limit of normal;
12. Be considered to be at imminent risk of suicide or have a past-year history of a serious suicide attempt (defined as an attempt that results in or requires medical treatment) based on response to queries within eligibility screening about suicidal ideation and attempts;
13. Have an uncontrolled systemic disease or a medical condition that may increase the risk associated with study participation or administration of study treatment or that may interfere with the interpretation of study results;
14. Be currently participating or has participated within the last 30 days prior to the start of this study in a drug, device, or other interventional research study;
15. Be pregnant or lactating;
16. In the Investigator's or Sponsor's (or designee) opinion, be inappropriate for the study, including those believed to be attempting to enter the study primarily for financial gain.

Primary outcomes:
measure: Percent of 20 Weeks Abstinent From Stimulants Following a 4-week Grace Period
timeFrame: 20 weeks
Secondary outcomes:
measure: Change From Screening in Participant-rated Quality of Life as Measured by the Treatment Effectiveness Assessment at Week 13, 25, and 33.
timeFrame: Weeks 13, 25, and 33
measure: Proportion of Responders in Early Remission at Week 25 as Measured by DSM-5 Criteria
timeFrame: 25 weeks
measure: Difference Between Groups in Clinical Global Impression of Change (CGIC) at Week 13, 25, and 33
timeFrame: Weeks 13, 25, and 33
measure: Difference Between Groups in Patient Global Impression of Change (PGIC) at Week 13, 25, and 33
timeFrame: Weeks 13, 25, and 33
Other outcomes:
Locations:
city: Bentonville
country: United States
facility: Pillar Clinical Research
state: Arkansas
city: Little Rock
country: United States
facility: Woodlands International Research Group
state: Arkansas
city: San Diego
country: United States
facility: Artemis Institute for Clinical Research
state: California
city: Lincolnwood
country: United States
facility: Pillar Clinical Research
state: Illinois
city: Dayton
country: United States
facility: Midwest Clinical Research Center
state: Ohio
city: DeSoto
country: United States
facility: InSite Clinical Research
state: Texas
city: Houston
country: United States
facility: HD Research
state: Texas
city: Richardson
country: United States
facility: Pillar Clinical Research
state: Texas
city: Clinton
country: United States
facility: Alpine Research
state: Utah
Study officials:
affiliation: InterveXion Therapeutics
name: Chief Medical Officer
role: STUDY_DIRECTOR
References: